UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-38537 TECTONIC THERAPEUTIC, INC. (E ...

Exhibit 99.1 Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights • Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025 • First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026 • Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhag ...

Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights • TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 • Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 • Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 million • Cash and cash equivalents were $185.1 million as of Ju ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per share TECX The Nasdaq Stock Market LLC Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Exhibit 99.3 Page Unaudited Interim Condensed Consolidated Financial Statements for the Three Months ended March 31, 2024 and 2023 Unaudited Condensed Consolidated Balance Sheets F-2 Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss F-3 Unaudited Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit F-4 Unaudited Condensed Consolidated Statements of Cash Flows F-5 Notes to Unaudited Condensed Consolidated Financial Statements F-6 F-1 ...

Avrobio (NASDAQ:AVRO) stock is on the move Thursday as the company is preparing for two major events taking place today.The first thing to note is that Avrobio is getting ready to undergo a merger with Tectonic Therapeutic. That merger is set to take place later today after investors approved it at an earlier shareholder meeting.Before that happens, traders will also see shares of AVRO stock undergo a reverse split. The company intends to enact a one-for-12 reverse stock split after markets close today. Thi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0710585 (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38537 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 81-0710585 (State or other jurisdiction of incorpora ...

CAMBRIDGE, Mass. & WATERTOWN, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”). Under the terms of the agreement, AVROBIO will acq ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, $0.0001 par value per share AVRO Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 | --- | --- | |----------------------------- ...